Ocular Manifestations of Sjögren's

Sjögren's is a systemic autoimmune disease in which the immune system attacks the body's moisture-producing glands, including the lacrimal glands that make the watery component of tears and the salivary glands that produce saliva. The result is marked dryness, classically of the eyes and the mouth. Reflecting a broader shift in how it is understood, the condition is increasingly described as Sjögren's disease rather than syndrome.

How it affects the eyes

By reducing tear production, Sjögren's is a leading cause of aqueous-deficient dry eye. Patients experience significant dryness, burning, a foreign-body sensation and light sensitivity, often more severe than in common evaporative dry eye, and the ocular surface can show substantial staining and damage.

A condition that needs coordinated care

Sjögren's is managed in partnership with rheumatology and other specialists, because it is a systemic disease. From the eye's perspective, the priorities are protecting and lubricating the ocular surface, controlling inflammation, and preserving comfort and vision. Many patients have a mixed picture, with meibomian gland dysfunction compounding the aqueous deficiency.

The role of ocular surface care

While Sjögren's itself requires systemic management, supporting the ocular surface remains essential, and light-based therapy can contribute where there is a coexisting evaporative or inflammatory component. LM™ LLLT photobiomodulation acts on inflammation and gland function and is recognised across the DEWS III driver groups (TFOS DEWS III, 2025, American Journal of Ophthalmology). Treatment is individualised by the clinician, recognising the more complex needs of autoimmune dry eye, and used within its cleared indications.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.